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Abstract 
Objectives: 1) Assess participants’ perceptions of severity, risk, and susceptibility to the novel H1N1 influenza virus and/or vaccine, 
vaccine benefits and barriers, and cues to action and 2) Identify predictors of participants’ intention to receive the novel H1N1 
vaccine. 
Design: Cross-sectional, descriptive study 
Setting: Local grocery store chain and university in the central Virginia area 
Participants: Convenience sample of adult college students and grocery store patrons 
Intervention: Participants filled out an anonymous, self-administered questionnaire based upon the Health Belief Model. 
Main Outcome Measures: Participants’ predictors of intention to receive the novel H1N1 vaccine 
Results: A total of 664 participants completed a questionnaire. The majority of participants were aged 25-64 years old (66.9%).  The 
majority were female (69.1%), Caucasian (73.7%), and felt at risk for getting sick from the virus (70.3%). Most disagreed that they 
would die from the virus (68.0%). Participants received novel H1N1 vaccine recommendations from their physicians (28.2%), 
pharmacists (20.7%), and nurses (16.1%). The majority intended to receive the H1N1 vaccine (58.1%). Participants were significantly 
more likely to intend to receive the H1N1 vaccine if they had lower scores on the perceived vaccine barriers domain (OR= 0.57, CI: 
0.35-0.93). Physicians’ recommendations (OR=0.26, CI: 0.11-0.62) and 2008 seasonal flu vaccination (OR=0.45, CI: 0.24-0.83) were 
significant predictors of intention to receive the H1N1 vaccine. 
Conclusions: Most participants felt at risk for getting the novel H1N1 virus and intended to receive the novel H1N1 vaccine. Educating 
patients about vaccine benefits and increasing healthcare professionals' vaccine recommendations may increase vaccination rates in 
future pandemics.    
 
 
Introduction 
The novel (2009) H1N1 influenza virus was first detected in 
the US in April 2009. By June 2009 the World Health 
Organization declared that the virus had reached pandemic 
status. The illness associated with the novel H1N1 influenza 
virus varied from mild (fever, muscle aches, and nausea) to 
severe (hospitalizations and deaths).
1
 Data from July 2009 
revealed approximately 37,000 cases in the US with a 
disproportionate number of cases in persons who were  
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younger than 25 years old.
1
 Similar to seasonal influenza, 
pregnant women,  those with pre-existing chronic disease 
states such as diabetes, asthma, heart disease, and kidney 
disease, and persons 65 years or older were at an increased 
risk of complications.
1
 In response to the pandemic, a novel 
H1N1 vaccine was developed. The initial target groups for 
receipt of the novel H1N1 vaccine were pregnant women, 
household contacts and caregivers for children < 6 months 
old, healthcare and emergency services personnel, all people 
from 6 months to 24 years old, and people ages 25-64 years 
old with pre-existing disease states that place them at risk for 
influenza complications.
2
 
 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2012, Vol. 3, No. 2, Article 74                         INNOVATIONS in pharmacy   2 
 
At the onset and during the pandemic, media coverage about 
the novel H1N1 influenza pandemic was widespread. 
However, little was known about perceptions of the novel 
H1N1 influenza virus in the United States and intention to 
receive its vaccine. Setbon and Raude analyzed responses 
from a telephone administered questionnaire in France which 
investigated participants’ perceptions of risk and illness 
related to the H1N1 virus, attitudes and worldviews about 
the pandemic, sociodemographics, seasonal influenza vaccine 
history, and intention to receive the novel H1N1 influenza 
vaccine. Approximately 60% of the 1,001 respondents 
intended to receive the novel H1N1 vaccine. Significant 
predictors of intention to vaccinate included previous receipt 
of a seasonal flu vaccine, feelings of worry related to H1N1, 
age > 60 years, perceived risk, and belief in conspiracy 
theories.
3
 Similarly, in a telephone administered survey 
conducted in Hong Kong, investigators examined factors 
related to acceptability of the H1N1 vaccine. A significant 
predictor of intention to receive the novel H1N1 vaccine was 
prior seasonal influenza vaccine history. In addition, 
recommendations from family members were a significant 
predictor at all three H1N1 vaccine price levels. Perceived 
side effects was only significant for the lowest cost H1N1 
vaccine, whereas, friends receiving the H1N1 vaccine was a 
significant predictor of intent only for the lowest and middle 
H1N1 cost scenarios.
4 
 
 
Our study investigated participants’ perceptions of the novel 
H1N1 influenza virus and identified factors that impacted 
intention to receive the novel H1N1 vaccine. This study was 
conducted prior to the novel H1N1 influenza vaccine being 
available in the community pharmacy setting. Information 
gained from this study about participants’ perceptions can be 
used by healthcare professionals in future influenza 
pandemic education and awareness campaigns.  
 
Objectives 
The objectives of this study were to: assess participants’ 
perceptions and attitudes about the severity, susceptibility, 
and risk of the novel H1N1 influenza virus and the novel 
H1N1 influenza vaccine, evaluate participants’ perceived 
benefits of and barriers to novel H1N1 influenza vaccination, 
identify participants’ cues to action, and determine the 
relationship between demographic and attitudinal variables 
and participants’ intention to receive novel H1N1 influenza 
vaccination.  
 
Methods 
Design and Sample 
This was a cross-sectional study conducted at Ukrop’s Super 
Markets, Inc. in the Central Virginia area and at Virginia 
Commonwealth University (VCU), Monroe Park Academic 
Campus, Richmond, Virginia. Adults ≥ 18 years of age were 
eligible to participate in the study. College students were 
targeted at VCU for participation due to many cases of the 
novel H1N1 influenza virus being observed in those less than 
25 years old.
2
 Given that those < 25 years old were 
considered a high-risk group for contracting the H1N1 virus, 
college students were purposely targeted at a University 
because the authors were concerned about obtaining 
participants in this age group at a grocery store. A 
convenience sample was utilized in both settings due to its 
accessible, inexpensive, and timely means of 
implementation.
5
 
 
Theoretical Framework 
The Health Belief Model (HBM) was the theoretical 
framework used in this study. The HBM is used to examine 
patient motivations for adapting a health-related behavior 
and used in assessing health-behavior interventions.  The 
HBM includes six key domains which influence health 
behaviors: perceived susceptibility, perceived severity, 
perceived benefits, perceived barriers, cues to action and 
self-efficacy. Perceived susceptibility addresses patient’s 
beliefs about their risk for getting a condition; whereas 
perceived severity relates to the patient’s concerns about the 
seriousness of a condition or illness. Perceived benefits are 
related to the outcomes of a certain behavior to reduce their 
susceptibility to or severity of an illness. Perceived barriers 
identify patient’s concerns or negative beliefs about a health 
behavior. Cues to action are strategies or information sources 
that promote adoption of a behavior. Self-efficacy measures 
the patient’s confidence to adopt a behavior or take action, 
e.g. accepting an immunization.
6 
The HBM has been used 
extensively to study vaccination beliefs and behaviors and in 
vaccination research to identify patient perceptions of 
disease and vaccination.
7-12
 HBM domains used in this study 
include perceived susceptibility, perceived severity, perceived 
benefits, perceived barriers, cues to action, and self-efficacy. 
 
Survey Instrument 
A 36-item questionnaire was developed to assess the study 
objectives. It contained 27 questions based upon the HBM, 3 
questions about participants’ intention to receive the vaccine 
and intention to vaccinate their child, if applicable, and 6 
demographic questions. The first portion of the questionnaire 
was separated into three 5-point Likert scaled (1 = strongly 
disagree to 5 = strongly agree) HBM groups: novel H1N1 
influenza virus statements (7 items), novel H1N1 influenza 
vaccine statements (9 items), and general vaccine statements 
(3 items). The statements addressed participants’ perceived 
susceptibility and severity of the novel H1N1 influenza virus 
and their perceived benefits and barriers to the novel H1N1 
vaccination. Two checklist questions assessed participants’ 
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cues to action (e.g., television, internet) about the novel 
H1N1 influenza virus and its vaccine. To identify other cues to 
action, six three-way (Yes/No/I don’t know) questions 
assessed past seasonal influenza vaccination history (2 items) 
and healthcare professionals’ recommendations to receive 
the novel H1N1 influenza vaccine (4 items). A four-point 
Likert scale (1 = very unlikely to 4 = very likely) was used for 
the two questions that directly asked participants  about their 
intention to receive the novel H1N1 influenza vaccine and 
their intention to vaccinate their child, if applicable. Six 
demographic variables were collected: age, gender, 
race/ethnicity, estimated annual income, highest education 
level completed, and whether or not the participant fell into a 
high-risk influenza group. The survey contained no 
identifiable patient information. The questionnaire was pre-
tested two times with pharmacists, student pharmacists, and 
Ukrop’s patrons for readability, comprehension of 
instructions, and clarity. Based upon feedback from the pre-
test, minor modifications regarding readability and clarity 
were made to the questionnaire. This research project was 
approved by the Institutional Review Board at Virginia 
Commonwealth University. 
 
Data Collection 
Ukrop’s pharmacists, student pharmacists, and pharmacy 
technicians invited Ukrop’s patrons to participate in the 
survey at the time of prescription pick-up/drop off, seasonal 
influenza vaccination, or while shopping in the grocery store. 
Patrons who agreed to participate received a copy of a cover 
letter and questionnaire and were instructed to return the 
completed questionnaire to the pharmacy staff. The 
researchers and student pharmacists distributed and 
administered the questionnaire to VCU students interested in 
participating in the study at the VCU University Student 
Commons. The questionnaire instructions defined the novel 
H1N1 influenza virus as: “The novel (new) H1N1 influenza 
virus is also known as "Swine Flu".”  Data was collected 
during a two-week period in October 2009. Data collection 
was completed prior to the availability of the H1N1 influenza 
vaccine in the community pharmacy setting.  
 
Participants were offered the opportunity to enter a raffle to 
win a gift card as an incentive for their time and participation 
in the survey. To protect participants’ confidentiality, a 
separate form for raffle entry was used. The raffle drawing 
was conducted after data collection was completed and after 
all completed raffle entry forms had been collected. A total of 
ten $50 gift cards were awarded to the raffle winners. 
 
Magenta for Office Forms Designer, Data Blocks (Version 
5.05, Gainesville, GA), Remark Office OMR Data Center, 
Gravic, Inc. (Version 6.0.4, Malvern, PA) was the software 
used for survey design and data entry. All hard copies of the 
completed questionnaires and raffle entry forms were stored 
in one of the researcher’s locked office. All scanned data was 
stored on a password protected computer. 
 
Data Analysis 
Descriptive statistics (mean, standard deviation, frequency) 
were used for all variables. The HBM-based statements were 
grouped according to domains (perceived susceptibility to the 
virus, perceived severity of the virus, perceived clinical 
barriers to vaccination, perceived access barriers to 
vaccination, perceived specific vaccine benefits, and 
perceived general vaccine benefits statements). Cronbach’s 
alpha was calculated for the domains with three or more 
items and Pearson’s correlation was used for the domain with 
two items to assess reliability. A scale mean was calculated 
for domains with an alpha coefficient or Pearson correlation > 
0.5. Cues to action were divided into three groups: virus 
information sources, vaccine information sources, and 
healthcare professionals’ recommendations. The number of 
cues to action for virus and vaccine information sources was 
summed to create an overall number of exposures to 
information for the two groups. The healthcare professionals’ 
recommendations (physician, pharmacist, and nurse) were 
kept as separate variables. Logistic regression was used to 
assess the relationship between demographic variables, 
health belief model domains, and number of cues to action or 
recommendations with participants’ intention to receive the 
novel H1N1 vaccine. For the logistic regression analysis, the 
variable intention to receive the novel H1N1 vaccine was 
dichotomized into a likely to vaccinate group (very likely and 
likely) or an unlikely to vaccinate group (very unlikely and 
unlikely). Race was collapsed into two categories Caucasian 
and Non-Caucasian due to a small number of participants in 
Non-Caucasian categories, and items in the perceived access 
barriers to vaccination domain were loaded into the model 
separately due to an alpha coefficient < 0.5. Age was grouped 
into three categories: < 25 years, 25-64 years, and ≥ 65 years. 
Age was categorized into these three levels to investigate if 
being in a high-risk age category (e.g. < 25 years for the H1N1 
influenza virus and > 65 years old for the seasonal influenza 
virus) was a significant predictor of intent to receive the novel 
H1N1 vaccine. A variable was created to identify VCU 
students and Ukrop’s patrons. For the healthcare 
professionals’ recommendations, responses of' “I don’t 
know” were categorized as missing and were not included in 
the data analysis. The statement, the novel H1N1 influenza 
vaccine is safe, was excluded from the perceived specific 
vaccine benefit domain due to poor correlation between the 
two domain items. Odds ratios and 95% confidence intervals 
are included. The a priori significance level was p < 0.05. 
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SAS/PC for Windows version 9.3 was used for data analysis 
(SAS Institute Inc., Cary, N.C.).  
 
Results  
Demographics and Seasonal Influenza Vaccine History 
A total of 664 individuals completed a questionnaire. The 
majority of participants were Ukrop’s patrons (86.3%). Most 
participants were aged 25-64 years old (66.9%). 
Approximately 69% of participants were female and the 
majority indicated Caucasian as their race/ethnicity (73.7 %). 
The most frequent estimated annual income reported was 
more than 55,000 (31.3%). Over 36% of the participants 
reported some college as their highest education level. The 
majority of participants were not a member of a high risk 
influenza group (52.9%) but had received a seasonal influenza 
vaccine prior to 2008 (75.0%) and in 2008 (57.6%). A 
summary of this information is presented in Table 1.  
 
Demographics and Vaccination History as Predictors of 
Intention to Receive the Novel H1N1 Vaccine 
The receipt of a seasonal influenza vaccine last year was a 
significant predictor of intention to receive the novel H1N1 
influenza vaccine. Those who did not receive a seasonal 
influenza vaccine in 2008 were less likely to intend to receive 
a novel H1N1 influenza vaccine (OR=0.45, CI: 0.24-0.83). 
There were no other significant demographic predictor 
variables in relation to the participant’s intention to receive 
the novel H1N1 vaccine (Table 3). 
 
Health Belief Model Domains as Predictors of Intention to 
Receive the Novel H1N1 Vaccine 
The scale means for the perceived severity and perceived 
susceptibility of the novel H1N1 virus domains were 3.02 (SD± 
0.76) and 3.72 (SD ± 0.76), respectively. The scale mean for 
the perceived clinical barriers domain was 2.38 (SD ± 0.68).  A 
summary of this information is presented in Table 2.  
 
Participants who perceived lower clinical barriers were more 
likely to intend to receive the novel H1N1 vaccine (OR=0.57, 
CI: 0.35-0.93). Perceptions of susceptibility, severity, general 
vaccine benefits, and vaccine access barriers were not 
significant predictors of intention to vaccinate (Table 3).  
 
Cues to Action as Predictors of Intention to Receive the 
Novel H1N1 Vaccine 
Participants received novel H1N1 vaccine recommendations 
from their physicians (28.2%), pharmacists (20.7%), and 
nurses (16.1%) (Table 2). Physicians’ recommendations to 
receive the novel H1N1 influenza vaccine were a significant 
predictor of intent to receive the vaccine. Those who did not 
receive a recommendation from their physician were less 
likely to intend to receive the H1N1 vaccine as compared to 
those who had received a physician’s recommendation to 
receive the vaccine (OR=0.26, CI: 0.11-0.62) (Table 3). Other 
information sources about the novel H1N1 influenza virus and 
its vaccine and nurse or pharmacist recommendations were 
not found to be significant predictors of intent to receive the 
vaccine.  
 
Discussion 
One of the significant predictors for intention to receive the 
novel H1N1 vaccine in this study was receipt of a seasonal 
influenza vaccine in the 2008 influenza season. This has 
previously been reported in an internet-based survey of over 
2,000 individuals in the United States in which 39.7% of the 
population was vaccinated against seasonal influenza. 
Researchers found that participants were twice as likely to 
intend to receive the novel H1N1 vaccine if they had received 
a seasonal influenza vaccine.
13
 In our study, the proportion of 
participants who had a seasonal influenza vaccine prior to 
2008 was 75%. In a study conducted in France, it was found 
that those with a history of a seasonal influenza vaccine were 
over 3.3 times more likely to intend to receive the novel 
H1N1 vaccine.
3
 Similarly, Lau et al.’s study conducted in Hong 
Kong showed that those with a history of an influenza 
vaccination were 2.59 to 3.13 times more likely to intend to 
receive the novel H1N1 vaccine compared to those who had 
not.
4
 In addition, a study in  Sydney, Australia found that 
participants who had a history of seasonal influenza 
vaccination in either 2008 or 2009 were 2.7 times more likely 
to intend to receive the novel H1N1 influenza vaccine.
14  
Interestingly, it was also reported that non-Caucasian ethnic 
groups were more willing to accept the H1N1 vaccine.
14
 In 
our study, race/ethnicity was not a significant predictor of 
intention to vaccinate when Caucasian and Non-Caucasian 
groups were compared. These studies and our work indicate 
that those with a history of vaccination may be more likely to 
intend to receive a new vaccine in a pandemic situation. This 
may be due to the participant’s comfort level or experience 
with vaccines, personal health beliefs, or previous experience 
with influenza and/or other disease. These results also 
suggest that targeting those without a vaccine history may 
increase vaccination rates by reaching out to a population 
that would be less likely to vaccinate during a pandemic. 
 
We found that participants were more likely to intend to 
receive the novel H1N1 vaccine if a physician had 
recommended it. A study by Maurer and colleagues also 
found that healthcare professionals’ recommendations to 
receive the novel H1N1 influenza vaccine were influential in 
the participant’s decision to receive the H1N1 vaccine.
15
 In 
other studies, it has been shown that a physician or nurse’s 
recommendation to receive a seasonal influenza vaccine was 
significantly associated with the patient’s intention or 
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acceptance of the vaccine.
9, 16, 17, 18  
In our study, the overall 
number of healthcare professionals’ recommendations to 
receive the novel H1N1 vaccine was low. Participants 
indicated that they received recommendations from their 
physicians (28.2%), pharmacists (20.7%), and nurses (16.1%). 
This signifies a need to target both patients and healthcare 
professionals with awareness and educational campaigns 
during a pandemic situation. Healthcare professionals should 
incorporate vaccine recommendations and education in their 
day-to-day activities during a pandemic.
19
 Specifically, our 
study shows that a recommendation from a physician may 
positively impact the participant’s intention to vaccinate. 
Efforts to increase physician’s vaccine recommendations to 
patients should continue to be a focus of public health 
initiatives. Although not significant in our study, pharmacists 
can play many roles to increase vaccination rates and 
different roles should be further investigated for impact. For 
example, pharmacists can serve as an advocate for 
immunizations, administer vaccines, or invite other 
healthcare professionals to immunize patients at their 
practice site.
20
 It has been shown that pharmacist-
administered influenza vaccines  have increased  overall 
influenza vaccination rates.
21 
Pharmacists’ increasing role in 
public health issues, such as immunizations and disease 
prevention, continues to grow.
22,23
 The pharmacist’s role and 
impact on public health concerns should continue to be 
examined.  
 
Another concern is how the media portrays both seasonal 
and influenza pandemics. Media coverage about the H1N1 
virus was widespread during the early months of the 
pandemic. But in our study, other information sources, 
including the media, did not have a significant impact on 
participant’s intention to accept the novel H1N1 vaccine. The 
impact of the media on intention to accept a pandemic 
vaccine warrants further research.  
 
In our study, participant’s perceived susceptibility to the 
novel H1N1 virus was not a significant predictor. Our results 
are consistent with Lau and colleagues’ results for perceived 
susceptibility.
4
 However, Seale and colleagues found that 
participants in their study who felt at risk were almost twice 
as likely to intend to accept the novel H1N1 vaccine.
14
 In 
addition, Setbon and Raude identified that those who 
perceived a risk of contracting the novel H1N1 virus were 1.4 
times more likely to intend to receive the novel H1N1 
vaccine.
3 
 We did not find participant’s perceived severity of  
the novel H1N1 virus to be a significant predictor of intent to 
accept the H1N1 vaccine. In contrast, a telephone survey of 
over 1,100 adults in Australia, found that participants were 
1.8 times more likely to accept the novel H1N1 vaccine if the 
virus was perceived as severe as compared to mild.
24 
Our 
results are supported by Lau and colleagues’ study which 
found that perceived severity was not a significant predictor 
of novel 2009 H1N1 vaccine intention.
4
  
 
A review of studies using the Health Belief Model theoretical 
framework found that for preventative health behaviors, such 
as influenza vaccination, the domains of perceived 
susceptibility, benefits, and barriers were predictive of health 
behaviors. The construct of perceived barriers was significant 
in all studies reviewed.  However, perceived severity was not 
as strongly associated with preventative health behaviors.
25
 
In our study perceived clinical barriers, history of influenza 
vaccination in the previous year, and physician 
recommendations were significant predictors of intention to 
accept the novel H1N1 vaccine, whereas perceived 
susceptibility was not. The perceived clinical barriers domain, 
which included perceptions of novel H1N1 vaccine-related 
side-effects, sickness, pain, and death, in our study was 
significant. These four perceptions indicate key areas where 
health care professionals can educate patients about vaccine-
related adverse events and address patient’s concerns.  
 
A physician-led strategy that would help increase influenza 
vaccine uptake could include improving the amount of 
vaccine recommendations and awareness along with 
education on vaccine benefits. Including an assessment of the 
community’s perceived severity of the influenza virus, 
perceived benefits of immunizations, and perceived barriers 
to accepting vaccinations may be a key way to create a 
targeted and effective educational campaign. This 
educational campaign could take place at many points of 
patient care, including but not limited to hospital discharge 
protocols, point of medication dispensing in community 
pharmacies, consultant pharmacists’ chart reviews in long-
term care facilities, and during patient interactions in the 
ambulatory care setting. In addition, providing vaccines at 
areas of convenience, such as school-based immunizations, 
may help to increase the uptake of a pandemic vaccine.
18 
 
Limitations 
One of the limitations of this study is that the researchers 
used a convenience sample to recruit participants; therefore 
selection bias is a concern. It is possible that those who 
participated had different views about H1N1 than those who 
did not participate. The generalizability of the results of this 
study to different races and ethnicities is also limited by this 
study’s predominantly Caucasian (73.7%) participants. Also, 
patrons of Ukrop’s supermarkets may view vaccines more 
favorably compared to other groups because Ukrop’s 
Pharmacy has had a well-promoted and established 
immunization program including seasonal influenza for many 
years. This could be a reason for the majority (57.6%) of 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2012, Vol. 3, No. 2, Article 74                         INNOVATIONS in pharmacy   6 
 
participants receiving the 2008 seasonal influenza vaccine. 
Approximately 47.1% of participants in this study indicated 
that they were in a high risk influenza group. This may be due 
to the fact that the several of the respondents may have been 
patients picking up a prescription at the pharmacy and thus 
potentially in a high risk group. However, grocery store 
patrons were also approached to complete the survey. Also, 
the sampling of college age students on VCU academic 
campus potentially increased the number of participants who 
fell into one of the high risk novel H1N1 categories. Another 
factor limiting the generalizability of our results is that this 
study population reported a high estimated annual income, 
with our most common estimated income level reported 
being over $55,000. This may be considered similar to most 
household incomes of the central Virginia area in 2009; 
however, we are not sure if the participants responded with 
sole or household income to this question.
26
 Also, we did not 
collect information on if the respondent had seen a 
healthcare provider since the start of the pandemic. This 
information would have been useful in assessing the 
healthcare professionals’ recommendations to respondents 
about receiving the novel H1N1 vaccine.  
 
Conclusion 
In a group of grocery store or pharmacy patrons and 
students, most participants felt at risk for getting the novel 
H1N1 virus and intended to receive the novel H1N1 vaccine. 
Significant predictors of intention to receive the novel H1N1 
vaccine include lower perceived clinical barriers, history of 
receiving the 2008 seasonal influenza vaccine, and physicians’ 
recommendations. Educating patients about vaccine benefits 
and increasing healthcare professionals’ vaccine 
recommendations may positively impact vaccination rates in 
future pandemics.  
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                           Table 1. Demographic and seasonal influenza vaccine history of survey participants 
               
Items n (%) 
Age (n=620)  
  < 25 years 124 (20.0) 
  25 - 64 years 415 (66.9) 
  ≥ 65 years 81 (13.1) 
Gender (n=657) 
  Male  
  Female 
 
203 (30.9) 
454 (69.1) 
Race/Ethnicity (n=632) 
  Caucasian 
  African American 
  Hispanic 
  Asian/Pacific Islander 
  Native American 
  Other 
 
  Caucasian 
  Non-Caucasian 
 
466 (73.7) 
107 (16.9) 
6 (1.0) 
14 (2.2) 
10 (1.6) 
29 (4.6) 
 
466 (73.7) 
166 (26.3) 
Estimated Annual Income  (n=597) 
  Less than $10,000 
  $10,001 to $25,000 
  $25,001 to $40,000 
  $40,001 to $55,000 
  More than $55,000 
 
94 (15.8) 
86 (14.4) 
153 (25.6) 
77 (12.9) 
187 (31.3) 
Highest Education Level (n=647) 
  Some high school 
  High school or GED 
  Some college 
  Undergraduate degree 
  Graduate/professional degree 
 
27 (4.2) 
145 (22.4) 
236 (36.5) 
143 (22.1) 
96 (14.8) 
Member of High Risk Group (n=664) 
  Yes 
  No 
 
313 (47.1) 
351 (52.9) 
VCU student (n=664) 
  Yes 
  No 
 
91 (13.7) 
573 (86.3) 
History of a past seasonal influenza vaccine (n=652) 
  Yes 
  No 
 
489 (75.0) 
163 (25.0) 
History of a seasonal influenza vaccine last year (2008) (n=651) 
  Yes 
  No 
 
375 (57.6) 
276 (42.4) 
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Table 2. Summary Health Belief Model responses of survey participants 
 
Items n (%) Alpha  Range Mean (SD)
a
 
Perceived Severity of the Virus (n=637) 
  If I get the novel H1N1 influenza virus I will get sick. 
  If I get the novel H1N1 influenza virus I will lose income. 
  If I get the novel H1N1 influenza virus other members in  
  my home will get sick. 
  If I get the novel H1N1 influenza virus I will die. 
- 0.62 1 - 5 3.02 (±0.76) 
Perceived Susceptibility to the Virus (n=656) 
  I am at risk for getting the novel H1N1 influenza virus. 
  My family members are at risk for getting the novel  
  H1N1 influenza virus. 
  I feel knowledgeable about my risk of getting the novel  
  H1N1 influenza virus. 
- 0.69 1 - 5 3.72 (±0.76) 
Perceived Clinical Barriers to Vaccination (n=640) 
  I will have side effects from the novel H1N1 influenza  
  vaccine. 
  I will get sick from the novel H1N1 influenza vaccine. 
  I will die from the novel H1N1 influenza vaccine. 
  The novel H1N1 influenza vaccine will be painful. 
- 0.78 1 - 5 2.38 (±0.68) 
Perceived Access Barriers to Vaccination  - 0.22 1 - 5 - 
  The novel H1N1 influenza vaccine will be expensive.  
  (n=653) 
- - - 2.53 (± 0.88) 
  It is inconvenient to get the novel H1N1 influenza    
  vaccine. (n=657) 
- - - 2.66 (± 1.12) 
  There is a shortage of the novel H1N1 influenza vaccine. 
  (n=648) 
- - - 3.83 (± 0.99) 
Perceived Specific Vaccine Benefit      
  If I receive the novel H1N1 influenza vaccine, I will not  
  get sick from the novel H1N1 influenza virus. (n=653) 
 
- 
 
- 
 
1 - 5 
 
3.05 (± 0.92) 
Perceived General Vaccine Benefits (n=658)
b
 
  Vaccines prevent disease.  
  Vaccines are safe. 
- - 1 - 5 3.76 (± 0.80) 
Virus Information Sources (n=664)
c
 - - 0 - 11 3.56 (± 2.15) 
Vaccine Information Sources (n=664)
c
 - - 0 - 11 3.45 (± 2.18) 
Physician Recommendation (n=556)     
  Yes 157 (28.2)    
  No 399 (71.8) - - - 
Pharmacist Recommendation (n=546)     
  Yes 113 (20.7)    
  No 433 (79.3) - - - 
Nurse Recommendation (n=548)     
  Yes 88 (16.1)    
  No 460 (83.9) - - - 
aA scale mean was calculated for domains with an alpha coefficient or Pearson Correlation > 0.5.  
bPearson Correlation = 0.58 
cVirus and vaccine information sources included telephone, internet, radio, newspaper, family member, friend, physician, pharmacist, 
nurse, other healthcare provider, and other. The number of virus and vaccine source exposures was summed to create an overall number of 
exposures to virus or vaccine information. 
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Table 3. Demographic, seasonal influenza vaccine history, and HBM attitudinal variables associated 
with intention to receive the novel H1N1 influenza vaccine 
 
                       Likelihood of Intention to 
                Receive Vaccine (n = 360)
a,b
 
Items OR [95% CI] p-value 
Demographics    
Age (n=620)  0.12 
  < 25 years 0.27 [0.08 - 0.93] 0.04 
  25 - 64 years 1.0  
  ≥ 65 years 1.00 [0.37 - 2.74] 0.99 
Gender (n=657) 
  Male  
  Female 
 
1.0 
1.51[0.84 - 2.71] 
 
 
0.17 
Race/Ethnicity (n=632) 
  Caucasian 
  Non-Caucasian 
 
1.0 
1.26 [0.66 - 2.41] 
 
 
0.48 
Estimated Annual Income  (n=597)
 
 
  Less than $10,000 
  $10,001 to $25,000 
  $25,001 to $40,000 
  $40,001 to $55,000 
  More than $55,000 
 
4.38 [1.21 - 15.83] 
1.12 [0.46 - 2.75] 
1.0 
0.95 [0.40 - 2.27] 
0.95 [0.47 - 1.91] 
0.20 
0.02 
0.80 
 
0.91 
0.88 
Highest Education Level (n=647) 
  Some high school 
  High school or GED 
  Some college 
  Undergraduate degree 
  Graduate/professional degree 
 
0.27 [0.07 - 1.12] 
1.0 
0.44 [0.22 - 0.92] 
0.40 [0.17 - 0.91] 
0.86 [0.34 - 2.18] 
0.06 
0.07 
 
0.03 
0.03 
0.74 
Member of High Risk Group (n=664) 
  Yes 
  No 
 
1.0 
0.85 [0.45 - 1.62] 
 
 
0.63 
VCU student (n=664) 
  Yes 
  No 
 
1.0 
1.03 [0.31 - 3.43] 
 
 
0.96 
Seasonal Influenza Vaccine History   
History of a past seasonal influenza vaccine (n=652) 
  Yes 
  No 
 
1.0 
0.64 [0.32 - 1.27] 
 
 
0.20 
History of a seasonal influenza vaccine last year  (2008) 
(n=651) 
  Yes 
  No 
 
 
1.0 
0.45 [0.24 - 0.83] 
 
 
 
0.01 
Health Belief Model Domains   
Perceived Severity of the Virus (n=637) 
  If I get the novel H1N1 influenza virus I will get sick. 
  If I get the novel H1N1 influenza virus I will lose income. 
  If I get the novel H1N1 influenza virus other members in  
  my home will get sick. 
  If I get the novel H1N1 influenza virus I will die. 
1.24 [0.83 - 1.85] 0.30 
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Perceived Susceptibility to the Virus (n=656) 
  I am at risk for getting the novel H1N1 influenza virus. 
  My family members are at risk for getting the novel  
  H1N1 influenza virus. 
  I feel knowledgeable about my risk of getting the novel  
  H1N1 influenza virus. 
1.03 [0.68 - 1.54] 0.90 
Perceived Clinical Barriers to Vaccination (n=640) 
  I will have side effects from the novel H1N1 influenza  
  vaccine. 
  I will get sick from the novel H1N1 influenza vaccine. 
  I will die from the novel H1N1 influenza vaccine. 
  The novel H1N1 influenza vaccine will be painful. 
0.57 [0.35 - 0.93] 0.02 
Perceived Access Barriers to Vaccination    
  The novel H1N1 influenza vaccine will be expensive.  
  (n=653) 
1.07 [0.77 - 1.50] 0.68 
  It is inconvenient to get the novel H1N1 influenza    
  vaccine. (n=657) 
0.94 [0.74 - 1.19] 0.62 
  There is a shortage of the novel H1N1 influenza vaccine. 
  (n=648) 
0.89 [0.67 - 1.19] 0.44 
Perceived Specific Vaccine Benefit   
  If I receive the novel H1N1 influenza vaccine, I will not  
  get sick from the novel H1N1 influenza virus. (n=653) 
1.25 [0.92 - 1.70] 0.16 
Perceived General Vaccine Benefits (n=658)
 
 
  Vaccines prevent disease.  
  Vaccines are safe. 
1.42 [0.97 - 2.06] 0.07 
Virus Information Sources (n=664)
 
 0.92 [0.76 - 1.12] 0.42 
Vaccine Information Sources (n=664)
 
 1.15 [0.94 - 1.40] 0.17 
Physician Recommendation (n=556)   
  Yes 1.0  
  No 0.26 [0.11 - 0.62] 0.002 
Pharmacist Recommendation (n=546)   
  Yes 1.0  
  No 0.90 [0.39 - 2.05] 0.80 
Nurse Recommendation (n=548)   
  Yes 1.0  
  No 0.84 [0.31 - 2.26] 0.73 
an = 360 due to missing responses  
bLikelihood ratio for the model intention to receive vaccine; χ2 = 111.22 , p < 0.0001.  
 
 
